CervoMed Phase 2b DLB trial fails primary and secondary endpoints; neflamapimod no better than placebo

CervoMed Inc.

Neflamapimod did not demonstrate statistically significant effects vs placebo on CDR-SB, TUG, NTD, or CGIC at 16 weeks.
Target plasma drug concentrations were not achieved during double-blind phase, likely negatively impacting results.
Favorable safety/tolerability profile with no new safety signal identified.
Company pausing all Phase 3 preparations for early-stage DLB until full analysis complete.
Full double-blind data expected January 2025; open-label first 16 weeks data expected late Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.